The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Subscribe To Our Newsletter & Stay Updated
